Ignite Creation Date:
2025-12-26 @ 10:20 PM
Ignite Modification Date:
2026-01-16 @ 8:36 PM
Study NCT ID:
NCT03298412
Status:
TERMINATED
Last Update Posted:
2020-09-11
First Post:
2017-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
Sponsor:
Amgen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
20150291
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None